CytomX Therapeutics (NASDAQ:CTMX) Cut to "Hold" at StockNews.com

StockNews.com downgraded shares of CytomX Therapeutics (NASDAQ:CTMX - Free Report) from a buy rating to a hold rating in a research note issued to investors on Monday.

Other equities research analysts also recently issued research reports about the company. Wedbush reissued an "outperform" rating and issued a $5.00 price target on shares of CytomX Therapeutics in a report on Friday, March 7th. HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $5.02.

CytomX Therapeutics Stock Down 13.5 %

Shares of NASDAQ CTMX traded down $0.07 during trading hours on Monday, hitting $0.47. 1,104,097 shares of the stock were exchanged, compared to its average volume of 2,632,126. The company has a market cap of $37.65 million, a PE ratio of 2.76 and a beta of 1.33. CytomX Therapeutics has a 12 month low of $0.46 and a 12 month high of $5.85. The firm has a fifty day moving average price of $0.72 and a 200-day moving average price of $0.94.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 EPS for the quarter, beating the consensus estimate of ($0.23) by $0.45. The firm had revenue of $38.09 million during the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. As a group, equities analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CTMX. FMR LLC boosted its holdings in shares of CytomX Therapeutics by 17.3% in the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock valued at $335,000 after acquiring an additional 41,949 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company's stock valued at $1,798,000 after purchasing an additional 16,359 shares during the last quarter. Geode Capital Management LLC grew its position in CytomX Therapeutics by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company's stock worth $948,000 after purchasing an additional 34,032 shares during the period. Virtu Financial LLC acquired a new stake in CytomX Therapeutics during the 3rd quarter worth about $104,000. Finally, Traphagen Investment Advisors LLC purchased a new position in shares of CytomX Therapeutics during the 4th quarter valued at about $31,000. Institutional investors and hedge funds own 67.77% of the company's stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.